Epidermal growth factor receptor mutations in lung cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib

Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Druker, B. J., Tamura, S., Buchdunger, E., Ohno-Jones, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 3,652

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527

ERBB receptors and cancer: the complexity of targeted inhibitors

Hynes, N. E., & Lane, H. A. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1609 · Cited by 3,379

The Consensus Coding Sequences of Human Breast and Colorectal Cancers

Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104

Investigating regulated signaling pathways in therapeutic targeting of non-small cell lung carcinoma

Alam, M., Hasan, G. M., Eldin, S. M., Adnan, M., Riaz, M. B., Islam, A., Khan, I., & Hassan, M. I. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114452 · Cited by 52

Unlocking the potential of PROTACs: A comprehensive review of protein degradation strategies in disease therapy

Bhole, R. P., Kute, P. R., Chikhale, R. V., Bonde, C. G., Pant, A., & Gurav, S. S. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106720 · Cited by 49

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study

Bian, D., Sun, L., Hu, J., Duan, L., Xia, H., Zhu, X., Sun, F., Zhang, L., Yu, H., Xiong, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40349-z · Cited by 49

New pyrazolyl-thiazolidinone/thiazole derivatives as celecoxib/dasatinib analogues with selective COX-2, HER-2 and EGFR inhibitory effects: design, synthesis, anti-inflammatory/anti-proliferative activities, apoptosis, molecular modelling and ADME studies

Fadaly, W. A. A., Zidan, T. H., Kahk, N. M., Mohamed, F. E. A., Abdelhakeem, M. M., Khalil, R. G., & Nemr, M. T. M. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2281262 · Cited by 48

Novel quinazolin-2-yl 1,2,3-triazole hybrids as promising multi-target anticancer agents: Design, synthesis, and molecular docking study

Hamaky, N. F. M. E., Hamdi, A., Bayoumi, W. A., Elgazar, A. A., & Nasr, M. N. A. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107437 · Cited by 48

Advances in molecular‐based personalized non‐small‐cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance

Jotte, R. M., & Spigel, D. R. (2015) · Cancer Medicine · doi:10.1002/cam4.506 · Cited by 51

Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma

Ilié, M., Hofman, V., Bonnetaud, C., Havet, K., Lespinet‐Fabre, V., Coëlle, C., Tanga, V., Vénissac, N., Mouroux, J., & Hofman, P. M. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-0963-z · Cited by 48

Malignant Pleural Effusion Supernatants Are Substitutes for Metastatic Pleural Tumor Tissues in EGFR Mutation Test in Patients with Advanced Lung Adenocarcinoma

Liu, D., Lu, Y., Hu, Z., Wu, N., Nie, X., Xia, Y., Han, Y., Li, Q., Zhu, G., & Bai, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089946 · Cited by 48

Gallic acid abolishes the EGFR/Src/Akt/Erk-mediated expression of matrix metalloproteinase-9 in MCF-7 breast cancer cells

Chen, Y., Lin, K.-N., Jhang, L.-M., Huang, C., Lee, Y., & Chang, L. (2016) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2016.04.025 · Cited by 49

Management of brain metastasized non-small cell lung cancer (NSCLC) – From local treatment to new systemic therapies

Tsakonas, G., Petris, L. D., & Ekman, S. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.02.004 · Cited by 48

Epithelial‐to‐mesenchymal transition and its role in EGFR‐mutant lung adenocarcinoma and idiopathic pulmonary fibrosis

Sakuma, Y. (2017) · Pathology International · doi:10.1111/pin.12553 · Cited by 48

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors

Wu, S., Chang, Y., Yu, C., Yang, P., & Shih, J. (2017) · ERJ Open Research · doi:10.1183/23120541.00092-2016 · Cited by 48

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Floc’h, N., Lim, S., Bickerton, S., Ahmed, A., Orme, J. P., Urosevic, J., Martin, M. J., Cross, D. A. E., Cho, B. C., & Smith, P. D. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0103 · Cited by 48

Epidermal Growth Factor Receptors with Tyrosine Kinase Domain Mutations Exhibit Reduced Cbl Association, Poor Ubiquitylation, and Down-regulation but Are Efficiently Internalized

Padrón, D., Sato, M., Shay, J. W., Gazdar, A. F., Minna, J. D., & Roth, M. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0484 · Cited by 48

Dacomitinib, a new therapy for the treatment of non-small cell lung cancer

Brzezniak, C. E., Carter, C. A., & Giaccone, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.758714 · Cited by 48

A Sweet New Role for EGFR in Cancer

Engelman, J. A., & Cantley, L. C. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.008 · Cited by 48

WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors

Sakuma, Y., Yamazaki, Y., Nakamura, Y., Yoshihara, M., Matsukuma, S., Nakayama, H., Yokose, T., Kameda, Y., Koizume, S., & Miyagi, Y. (2011) · Laboratory Investigation · doi:10.1038/labinvest.2011.187 · Cited by 48

Chemical and Pathway Proteomics

Kruse, U., Bantscheff, M., Drewes, G., & Hopf, C. (2008) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r800006-mcp200 · Cited by 48

Inhibition of mitochondrial glutaminase activity reverses acquired erlotinib resistance in non-small cell lung cancer

Xie, C., Jin, J., Bao, X., Zhan, W.-H., Han, T.-Y., Gan, M., Zhang, C., & Wang, J. (2016) · Oncotarget · doi:10.18632/oncotarget.6311 · Cited by 47

The positive impact of cytological specimens for EGFR mutation testing in non-small cell lung cancer: a single South East Asian laboratory's analysis of 670 cases

Pang, B., Matthias, D., Ong, C. W., Dhewar, A. N., Gupta, S., Lim, G. L., Nga, M. E., Seet, J. E., Qasim, A., Chin, T. M., et al. (2012) · Cytopathology · doi:10.1111/j.1365-2303.2012.01000.x · Cited by 47

Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer

Du, Z., Kan, H., Sun, J., Liu, Y., Gu, J., Akemujiang, S., Zou, Y., Jiang, L., Wang, Q., Li, C., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101266 · Cited by 47

Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma

Schneeberger, V. E., Ren, Y., Luetteke, N., Huang, Q., Chen, L., Lawrence, H. R., Lawrence, N. J., Haura, E. B., Koomen, J. M., Coppola, D., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3356 · Cited by 49

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells

Li, X.-Y., WU, J.-Z., Cao, H., Ma, R., Wu, J., Zhong, Y., & Feng, J. (2013) · Oncology Reports · doi:10.3892/or.2013.2298 · Cited by 47

EGFR signaling pathway and related-miRNAs in age-related diseases: the example of miR-221 and miR-222

Teixeira, A. L., Gomes, M. P., & Medeiros, R. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00286 · Cited by 47

Including Total EGFR Staining in Scoring Improves EGFR Mutations Detection by Mutation-Specific Antibodies and EGFR TKIs Response Prediction

Wu, S., Chang, Y., Lin, J., Wu, C., Chen, H., Tsai, M., Lee, Y.-C., Yu, C., & Shih, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023303 · Cited by 47

Addition of S-1 to the Epidermal Growth Factor Receptor Inhibitor Gefitinib Overcomes Gefitinib Resistance in Non–small cell Lung Cancer Cell Lines withMETAmplification

Okabe, T., Okamoto, I., Tsukioka, S., Uchida, J., Hatashita, E., Yamada, Y., Yoshida, T., Nishio, K., Fukuoka, M., Janne, P. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2251 · Cited by 47

Soluble Epidermal Growth Factor Receptors (sEGFRs) in Cancer: Biological Aspects and Clinical Relevance

Maramotti, S., Paci, M., Manzotti, G., Rapicetta, C., Gugnoni, M., Galeone, C., Cesario, A., & Lococo, F. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040593 · Cited by 47

Induction of Cbl-dependent epidermal growth factor receptor degradation in Ling Zhi-8 suppressed lung cancer

Lin, T., Hsu, H.-Y., Sun, W.-H., Wu, T.-H., & Tsao, S.-M. (2017) · International Journal of Cancer · doi:10.1002/ijc.30649 · Cited by 47

Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle

Patel, H., Pawara, R. H., Ansari, A., Noolvi, M. N., & Surana, S. J. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.03.039 · Cited by 47

Suppression of lung cancer progression by isoliquiritigenin through its metabolite 2, 4, 2’, 4’-Tetrahydroxychalcone

Chen, C., Shenoy, A. K., Padia, R. N., Fang, D., Jing, Q., Yang, P., Su, S.-B., & Huang, S. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0902-4 · Cited by 47

Targeting the interaction of AIMP2-DX2 with HSP70 suppresses cancer development

Lim, S., Cho, H. Y., Kim, D. G., Roh, Y., Son, S.-Y., Mushtaq, A. U., Kim, M., Bhattarai, D., Sivaraman, A., Lee, Y., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0415-2 · Cited by 47

Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment

Ghosh, S., Marrocco, I., & Yarden, Y. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.04.002 · Cited by 48

Targeting Malignant Mitochondria With Therapeutic Peptides

Constance, J. E., & Lim, C. S. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.75 · Cited by 48

Determinants of Survival in Advanced Non–Small-Cell Lung Cancer in the Era of Targeted Therapies

Bauml, J. M., Mick, R., Zhang, Y., Watt, C. D., Vachani, A., Aggarwal, C., Evans, T. L., & Langer, C. J. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.05.002 · Cited by 47

Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study

Pilotto, S., Rossi, A., Vavalà, T., Follador, A., Tiseo, M., Galetta, D., Morabito, A., Di Maio, M., Martelli, O., Caffo, O., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.016 · Cited by 46

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines

Passiglia, F., Pilotto, S., Facchinetti, F., Bertolaccini, L., Re, M. D., Ferrara, R., Franchina, T., Malapelle, U., Menis, J., Passaro, A., et al. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102858 · Cited by 48

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [11C]erlotinib and [18F]afatinib in lung cancer-bearing mice

Slobbe, P., Windhorst, A. D., van Walsum, M., Smit, E. F., Niessen, H. G., Solca, F., Stehle, G., van Dongen, G. A. M. S., & Poot, A. J. (2015) · EJNMMI Research · doi:10.1186/s13550-015-0088-0 · Cited by 46

JAK 2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

Harada, D., Takigawa, N., Ochi, N., Ninomiya, T., Yasugi, M., Kubo, T., Takeda, H., Ichihara, E., Ohashi, K., Takata, S., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02363.x · Cited by 46

Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer

Kimura, H., Ohira, T., Uchida, O., Matsubayashi, J., Shimizu, S., Nagao, T., Ikeda, N., & Nishio, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2013.12.012 · Cited by 46

Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors

Slobbe, P., Windhorst, A. D., van Walsum, M., Schuit, R. C., Smit, E. F., Niessen, H. G., Solca, F., Stehle, G., van Dongen, G. A. M. S., & Poot, A. J. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.06.005 · Cited by 46

Epidermal growth factor receptor mutation in lung adenocarcinoma in India: A single center study

Doval, D. C., Choudhury, K. D., Talwar, V., Gupta, S., Mehta, A., Azam, S., & Batra, U. (2013) · Journal of Carcinogenesis · doi:10.4103/1477-3163.114970 · Cited by 46

Importance of Molecular Features of Non–Small Cell Lung Cancer for Choice of Treatment

Moran, C. A. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.12.057 · Cited by 46

Characterization of Irreversible Kinase Inhibitors by Directly Detecting Covalent Bond Formation: A Tool for Dissecting Kinase Drug Resistance

Klüter, S., Simard, J. R., Rode, H. B., Grütter, C., Pawar, V. T., Raaijmakers, H. C. A., Barf, T. A., Rabiller, M., van Otterlo, W. A. L., & Rauh, D. (2010) · ChemBioChem · doi:10.1002/cbic.201000352 · Cited by 46

Analytic performance studies and clinical reproducibility of a real-time PCRassay for the detection of epidermal growth factor receptor gene mutations informalin-fixed paraffin-embedded tissue specimens of non-small cell lungcancer

O’Donnell, P., Ferguson, J., Shyu, J., Current, R., Rehage, T., Tsai, J., Christensen, M. L., Tran, H. B., Chien, S., Shieh, F., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-210 · Cited by 46

Identification of module biomarkers from the dysregulated ceRNA–ceRNA interaction network in lung adenocarcinoma

Shao, T., Wu, A., Chen, J., Chen, H., Lu, J., Bai, J., Li, Y., Xu, J., & Li, X. (2015) · Molecular BioSystems · doi:10.1039/c5mb00364d · Cited by 46

Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase–AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non–Small Cell Lung Cancer Cells

Ko, J., Ciou, S., Jhan, J.-Y., Cheng, C., Su, Y.-J., Chuang, S., Lin, S., Chang, C., & Lin, Y. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0051 · Cited by 46

Genomics and Cancer Drug Resistance

Rodrigues, A. S., Dinis, J., Gromicho, M., Martins, C., Laires, A., & Rueff, J. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112799857549 · Cited by 47

Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas

Koriyama (2010) · Oncology Reports · doi:10.3892/or_00000736 · Cited by 46

Adapting conventional cancer treatment for immunotherapy

Qiao, J., Liu, Z., & Fu, Y. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1393-4 · Cited by 47

(Z)3,4,5,4′-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level

Fan, X., Yao, X., Xu, S., Wong, V. K. W., He, J., Ding, J., Xue, W., Mujtaba, T., Michelangeli, F., Huang, M., et al. (2015) · Scientific Reports · doi:10.1038/srep16348 · Cited by 46

Deep mutational analysis reveals functional trade-offs in the sequences of EGFR autophosphorylation sites

Cantor, A. J., Shah, N. H., & Kuriyan, J. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803598115 · Cited by 46

Cell type–dependent bimodal p53 activation engenders a dynamic mechanism of chemoresistance

Yang, R., Huang, B. Y., Zhu, Y., Li, Y., Liu, F., & Shi, J. (2018) · Science Advances · doi:10.1126/sciadv.aat5077 · Cited by 46

The long non-coding RNA PIK3CD-AS2 promotes lung adenocarcinoma progression via YBX1-mediated suppression of p53 pathway

Zheng, X., Zhang, J., Fang, T., Wang, X., Wang, S., Ma, Z., Xu, Y., Han, C., Sun, M., Xu, L., et al. (2020) · Oncogenesis · doi:10.1038/s41389-020-0217-0 · Cited by 47

miR-146b-5p Enhances the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors by Regulating the IRAK1/NF-κB Pathway

Liu, Y., Tsai, M., Wu, S., Chang, T., Tsai, T.-H., Gow, C., Wang, H., & Shih, J. (2020) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2020.09.015 · Cited by 46

c-CSN: Single-Cell RNA Sequencing Data Analysis by Conditional Cell-Specific Network

Li, L., Dai, H., Fang, Z., & Chen, L. (2021) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.05.005 · Cited by 46

Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators

Wang, S. E., Yu, Y., Criswell, T. L., DeBusk, L. M., Lin, P., Zent, R., Johnson, D. H., Ren, X., & Arteaga, C. L. (2010) · Oncogene · doi:10.1038/onc.2010.112 · Cited by 47

Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation

Ulivi, P., Zoli, W., Capelli, L., Chiadini, E., Calistri, D., & Amadori, D. (2013) · Molecular and Clinical Oncology · doi:10.3892/mco.2013.100 · Cited by 46

Recent Advances in Structural Optimization of Quinazoline-Based Protein Kinase Inhibitors for Cancer Therapy (2021–Present)

Abdel‐Mohsen, H. T., Anwar, M. M., Ahmed, N. S. I., El‐Karim, S. S. A., & Abdelwahed, S. H. (2024) · Molecules · doi:10.3390/molecules29040875 · Cited by 45

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients

Chang, J. W., Liu, H.-P., Hsieh, M., Fang, Y., Hsieh, M., Hsieh, J., Chiu, Y.-T., Tsai, H., Chen, Y., Chen, Y., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.01.009 · Cited by 45

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients

Yam, I., Lam, D. C.-L., Chan, K., Ho, J., Ip, M., Lam, W. K., Chan, T., & Chan, V. W. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182558198 · Cited by 45

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

Patton, S. J., Normanno, N., Blackhall, F. H., Murray, S. J., Kerr, K. M., Dietel, M., Filipits, M., Benlloch, S., Popat, S., Stahel, R. A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.353 · Cited by 45

Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors

Nishida, T., Doi, T., & Naito, Y. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.937707 · Cited by 45

Structural modelling and dynamics of proteins for insights into drug interactions

Werner, T., Morris, M. B., Dastmalchi, S., & Church, W. B. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.011 · Cited by 45

Genetic modifiers of EGFR dependence in non-small cell lung cancer

Sharifnia, T., Rusu, V., Piccioni, F., Bagul, M., Imielinski, M. B., Cherniack, A. D., Pedamallu, C. S., Wong, B., Wilson, F. H., Garraway, L. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412228112 · Cited by 48

Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer

Fong, J., Jacobs, R. J., Moravec, D. N., Uppada, S. B., Botting, G. M., Nlend, M., & Puri, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078398 · Cited by 45

Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways

Zhong, H. A., & Bowen, J. P. (2011) · Current Topics in Medicinal Chemistry · doi:10.2174/156802611795860924 · Cited by 45

Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer

Pantaleo, M. A., Nannini, M., Maleddu, A., Fanti, S., Nanni, C., Boschi, S., Lodi, F., Nicoletti, G., Landuzzi, L., Lollini, P., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn625 · Cited by 45

Serum Detection of Epidermal Growth Factor Receptor Gene Mutations Using Mutant-Enriched Sequencing in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Jiang, B., Liu, F., Yang, L., Zhang, W., Yuan, H., Wang, J., & Huang, G. (2011) · Journal of International Medical Research · doi:10.1177/147323001103900425 · Cited by 45

Epidermal Growth Factor Receptor–Mutant Lung Cancer

Piotrowska, Z., & Sequist, L. V. D. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000147 · Cited by 45

Synthesis and Evaluation of a Novel Deguelin Derivative, L80, which Disrupts ATP Binding to the C-terminal Domain of Heat Shock Protein 90

Lee, S.-C., Min, H., Choi, H., Kim, H. S., Kim, K.-C., Park, S., Seong, M. A., Seo, J. H., Park, H., Suh, Y., et al. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.096883 · Cited by 45

Structural pharmacological studies on EGFR T790M/C797S

Kong, L., Ma, R., Yao, M.-Y., Yan, X.-E., Zhu, S., Zhao, P., & Yun, C. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.04.138 · Cited by 45

Panobinostat sensitizes KRAS‐mutant non‐small‐cell lung cancer to gefitinib by targeting TAZ

Lee, W., Chen, P., Wu, W., Wu, H., Lan, C.-H., Huang, Y., Cheng, C., Chen, K., & Lin, C. (2017) · International Journal of Cancer · doi:10.1002/ijc.30888 · Cited by 47

Next-Generation Sequencing for Genotyping of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration Samples in Lung Cancer

Xie, F., Zheng, X., Mao, X., Zhao, R., Ye, J., Zhang, Y., & Sun, J. (2019) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2019.02.010 · Cited by 45

Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior

Dong, Z., Yan, S., Liu, B., Hao, Y., Lin, L., Chang, T., Sun, H., Wang, Y., Li, H., Wu, H., et al. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00199 · Cited by 45

Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer

Wu, J.-Y., & Shih, J.-Y. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s118071 · Cited by 44

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC

Pallis, A. G., & Syrigos, K. N. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2012.12.025 · Cited by 44

Timing of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Patients With Lung Cancer With EGFR Mutations

Morán, T., & Sequist, L. V. D. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.1858 · Cited by 44

Design, synthesis, anticancer activity and docking studies of novel quinazoline-based thiazole derivatives as EGFR kinase inhibitors

Raghu, M. S., Swarup, H. A., Shamala, T., Prathibha, B. S., Kumar, K. Y., Alharethy, F., Prashanth, M. K., & Jeon, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20300 · Cited by 44

CoHIT: a one-pot ultrasensitive ERA-CRISPR system for detecting multiple same-site indels

Liu, Y., Liu, X., Wei, D., Dang, L., Xu, X., Huang, S., Li, L., Wu, S., Wu, J., Liu, X., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49414-7 · Cited by 44

Exploiting Synthetic Lethal Interactions Between DNA Damage Signaling, Checkpoint Control, and p53 for Targeted Cancer Therapy

Morandell, S., & Yaffe, M. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-387665-2.00011-0 · Cited by 45

The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer.

Wang, S., Yu, B., Ng, C. C., Mercorella, B., Selinger, C. I., O’Toole, S. A., & Cooper, W. A. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.01.05 · Cited by 44

The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer

Metro, G., & Crinò, L. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.34 · Cited by 45

The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer

Kwak, E. L. (2011) · The Oncologist · doi:10.1634/theoncologist.2011-0087 · Cited by 44

Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease

Yarden, Y., & Wheeler, D. L. (2014) · Springer eBooks · doi:10.1007/978-1-4939-2053-2 · Cited by 44

Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients

Blumenthal, D. T., Dvir, A., Lossos, A., Tzuk-Shina, T., Lior, T., Limon, D., Yust‐Katz, S., Lokiec, A., Ram, Z., Ross, J. S., et al. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2237-3 · Cited by 45

New Insights in the Cytogenetic Practice: Karyotypic Chaos, Non-Clonal Chromosomal Alterations and Chromosomal Instability in Human Cancer and Therapy Response

Rangel, N., Forero‐Castro, M., & Rondón‐Lagos, M. (2017) · Genes · doi:10.3390/genes8060155 · Cited by 44

Non‐small cell lung cancer harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report

Huang, J., Wang, Y., Zhai, Y., & Wang, J. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12637 · Cited by 44

Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC

Jiang, L., Guo, F., Liu, X., Li, X., Qin, Q., Shu, P., Li, Y., & Wang, Y. (2019) · Scientific Reports · doi:10.1038/s41598-018-38068-3 · Cited by 44

Discovery of a Furanopyrimidine-Based Epidermal Growth Factor Receptor Inhibitor (DBPR112) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer

Lin, S., Hsu, Y. C., Peng, Y.-H., Ke, Y., Lin, W., Sun, H.-Y., Shiao, H., Kuo, F., Chen, P.-Y., Lien, T., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00722 · Cited by 44

Nanomedicine in Non-Small Cell Lung Cancer: From Conventional Treatments to Immunotherapy

García-Fernández, C., Fornaguera, C., & Borrós, S. (2020) · Cancers · doi:10.3390/cancers12061609 · Cited by 44

Combined Treatment with Erlotinib and a Transforming Growth Factor-β Type I Receptor Inhibitor Effectively Suppresses the Enhanced Motility of Erlotinib-Resistant Non–Small-Cell Lung Cancer Cells

Serizawa, M., Takahashi, T., Yamamoto, N., & Koh, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318279e942 · Cited by 44

A Subset of Lung Adenocarcinomas and Atypical Adenomatous Hyperplasia–Associated Foci Are Genotypically Related

Sartori, G., Cavazza, A., Bertolini, F., Longo, L., Marchioni, A., Costantini, M., Barbieri, F., Migaldi, M., & Rossi, G. (2008) · American Journal of Clinical Pathology · doi:10.1309/thu13f3jrjvwlm30 · Cited by 44

Structural basis of mutant-selectivity and drug-resistance related to CO-1686

Yan, X.-E., Zhu, S.-J., Liang, L., Zhao, P., Choi, H. G., & Yun, C.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.18588 · Cited by 43

The application of PROTAC in HDAC

Chen, S., Zheng, Y., Liang, B., Yin, Y., Yao, J., Wang, Q., Liu, Y., & Neamati, N. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115746 · Cited by 45

Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation

Zhu, Y., Ye, X., Wu, Y., Shen, H., Cai, Z., Xia, F., Min, W., Hou, Y., Wang, L., Wang, X., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00107 · Cited by 43

Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non–Small-Cell Lung Cancer Cells

Liu, J., Li, W., Gao, S., Wang, F., Li, X., Yu, H., Fan, L., Wei, W., Wang, H., & Sun, G. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.03.006 · Cited by 43

Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes

Locatelli-Sanchez, M., Couraud, S., Arpin, D., Riou, R., Bringuier, P., & Souquet, P.-J. (2013) · Lung · doi:10.1007/s00408-013-9482-4 · Cited by 43

EGFR mutation frequency and effectiveness of erlotinib: A prospective observational study in Danish patients with non-small cell lung cancer

Weber, B., Hager, H., Sørensen, B. S., McCulloch, T., Mellemgaard, A., Khalil, A. A., Nexø, E., & Meldgaard, P. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.11.023 · Cited by 43

Identification and Characterization of Cancer Mutations in Japanese Lung Adenocarcinoma without Sequencing of Normal Tissue Counterparts

Suzuki, A., Mimaki, S., Yamane, Y., Kawase, A., Matsushima, K., Suzuki, M., Goto, K., Sugano, S., Esumi, H., Suzuki, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073484 · Cited by 43

Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations

Furcht, C. M., Muñoz-Rojas, A. R., Nihalani, D., & Lazzara, M. J. (2012) · Oncogene · doi:10.1038/onc.2012.240 · Cited by 44

Epidermal Growth Factor Receptor Mutations

McLoughlin, E. M., & Gentzler, R. D. (2020) · Thoracic surgery clinics/Thorac. surg. clin. · doi:10.1016/j.thorsurg.2020.01.008 · Cited by 23

Molecular Targeted Therapy of Lung Cancer: EGFR Mutations and Response to EGFR InhibitorsPreprint

Haber, D. A., Bell, D. W., Sordella, R., Kwak, E. L., Godin-Heymann, N., Sharma, S. V., Lynch, T. J., & Settleman, J. E. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.043 · Cited by 112

Epidermal growth factor receptor mutations in lung adenocarcinoma

Siegelin, M. D., & Borczuk, A. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.147 · Cited by 234

Strategies for Overcoming Acquired Resistance to Epidermal Growth Factor Receptor–Targeted Therapies in Lung Cancer

Oxnard, G. R. (2012) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2012-0254-ra · Cited by 21

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms

Yamaoka, T., Ohba, M., & Ohmori, T. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112420 · Cited by 156